Financial Performance - The company's basic earnings per share for 2024 is 2.26 yuan, a decrease of 12.06% compared to 2.57 yuan in 2023 [1] - The net profit for 2024 is 1.5 billion yuan, showing a slight increase of 2.04% from 1.47 billion yuan in 2023 [1] - The total operating revenue for 2024 is 8.88 billion yuan, representing a growth of 13.85% from 7.8 billion yuan in 2023 [1] - The return on equity (ROE) for 2024 is 9.84%, down 33.65% from 14.83% in 2023 [1] - The net asset per share increased to 26.12 yuan, a rise of 39.23% from 18.76 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 4.0235 million shares, accounting for 21.15% of the circulating shares, with an increase of 1.5735 million shares compared to the previous period [1] - Notable new entrants among the top shareholders include Hui Tian Fu Value Selection Mixed A and Hui Tian Fu Innovative Medicine Mixed, with holdings of 0.6927 million shares and 0.4773 million shares respectively [2] - Several shareholders exited the top ten list, including Hong Kong Central Clearing Limited and Feng Xinglai, with holdings of 0.3240 million shares and 0.1590 million shares respectively [2][3] Dividend Distribution - The company has proposed a dividend distribution plan of 10 shares for every 4 shares held, along with a cash dividend of 6.5 yuan (including tax) [4]
爱迪特:2024年报净利润1.5亿 同比增长2.04%
Tong Hua Shun Cai Bao·2025-04-28 18:29